| Titolo |
Pubblicato in |
Anno |
| INTEGRATION OF CD200, CD43 AND ROR1 IN MULTIPARAMETER FLOW CYTOMETRY (MFC) ROUTINE PANELS FOR THE DIFFERENTIAL DIAGNOSIS OF B-CELL LYMPHOPROLIFERATIVE DISORDERS (B-LPDS) |
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES |
2025 |
| Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results |
JOURNAL OF CLINICAL ONCOLOGY |
2024 |
| Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study |
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES |
2023 |
| The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi |
HEMATOLOGICAL ONCOLOGY |
2023 |
| Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL) |
HAEMATOLOGICA |
2023 |
| A prognostic model for patients with lymphoma and COVID-19. a multicentre cohort study |
BLOOD ADVANCES |
2022 |
| Bing-Neel syndrome coexisting with oligodendroglioma |
LEUKEMIA & LYMPHOMA |
2022 |
| Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL) |
LEUKEMIA & LYMPHOMA |
2022 |
| Donor cell derived mantle cell lymphoma in a HSCT sibling donor-recipient pair: intrinsic biological clock in lymphomagenesis |
LEUKEMIA & LYMPHOMA |
2022 |
| Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study |
HEMATOLOGICAL ONCOLOGY |
2022 |
| COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies |
BRITISH JOURNAL OF HAEMATOLOGY |
2021 |
| MRI versus CT and PET/CT in the preoperative assessment of Hodgkin and non-Hodgkin lymphomas |
HEMATO |
2021 |
| Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study |
LEUKEMIA |
2020 |
| COVID-19 in patients with hematologic disorders undergoing therapy: perspective of a large referral hematology center in Rome |
ACTA HAEMATOLOGICA |
2020 |
| Human herpesvirus-8–positive primary effusion lymphoma in HIV-negative patients: single institution case series with a multidisciplinary characterization |
CANCER CYTOPATHOLOGY |
2020 |
| Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy |
LEUKEMIA & LYMPHOMA |
2020 |
| The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma. a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) |
LEUKEMIA & LYMPHOMA |
2019 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy |
BLOOD |
2019 |
| Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders |
LEUKEMIA & LYMPHOMA |
2018 |
| PREDICTIVE FACTORS FOR INFECTIOUS ADVERSE EVENTS IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA TREATED WITH BENDAMUSTINE-RITUXIMAB (R)+/- R MAINTENANCE. RESULTS OF A RETROSPECTIVE ANALYSIS |
22nd Congress of the European-Hematology-AssociationHAEMATOLOGICA |
2017 |
